Healthcare costs factor high in Parkinson’s economic burden

Healthcare services contribute to nearly half the total expenses associated with Parkinson’s disease, but the loss of productivity and the financial burden on patients and their families also have a substantial impact, a study shows. The study estimated the average annual cost per patient with Parkinson’s disease is about…

Study Reviews Use of Acadia’s Nuplazid as Treatment for Psychosis Linked to Parkinson’s Disease

Acadia Pharmaceuticals‘ Nuplazid (pimavanserin) is a reliable treatment to manage hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), but its high cost and restricted access may limit its use in clinical practice, a new study says. The review, “Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis,”…